Ewelina Krol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ewelina Krol has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Boguslaw Szewczyk
Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk, ul. Abrahama 58, 80-307 Gdansk, Poland
18 shared publications - Gabriela Brzuska
Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland
7 shared publications - Gabriela Pastuch-Gawołek
Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology, B. Krzywoustego 4, 44-100 Gliwice, Poland
7 shared publications - Ilona Wandzik
Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Faculty of Chemistry, Silesian University of Technology, Krzywoustego 4, 44-100 Gliwice, Poland
7 shared publications - Daniel Růžek
Veterinary Research Institute Brno Czech Republic
5 shared publications Gabriela Brzuska
Laboratory of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, Gdansk 80-307, Poland
4 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by Microbiology Society in Journal of General Virology
- Vol. 107 (2)
Geographical and temporal trends of HIV-1 subtypes and drug resistance in China: a nationwide study over two decades (2003–2024)
Objective. This study aims to characterize the 20-year trends in human immunodeficiency virus 1 (HIV-1) subtypes and circulating recombinant forms (CRFs) in China, as well as patterns of transmitted drug resistance (TDR) to antiretroviral therapies commonly used in clinical practice. Methods. We analysed HIV-1 sequences from 81,563 individuals living in China between 2003 and 2024. Subtypes and CRFs were classified using COMET V2.4. Among these, pol gene sequences from 41,486 treatment-naïve individuals were used to assess TDR via the Stanford HIVdb genotypic resistance interpretation program. Results. Over the past two decades, CRF01_AE (43.9%) was the most prevalent HIV-1 strain in China, followed by CRF07_BC (19.0%), subtype B (12.3%), subtype C (8.4%) and CRF08_B (4.9%). However, subtype and CRF distributions varied considerably across provinces. CRF01_AE predominated in provinces such as Liaoning (92.4%), Guangxi (58.7%), Beijing (47.7%) and Hainan (44.8%), while CRF07_BC was dominant in Sichuan (63.6%), Chongqing (53.2%) and Xinjiang (82.7%). TDR analysis revealed elevated resistance to non-nucleoside reverse transcriptase inhibitors in certain provinces, including Yunnan (12.4%), Xinjiang (8.2%), Anhui (7.6%) and Henan (6.7%). In contrast, resistance to nucleoside reverse transcriptase inhibitors and integrase inhibitors remained low (Conclusion. Continued surveillance of HIV-1 genotypes and CRFs is critical, particularly in regions where routine genotypic testing is not implemented. Personalized antiretroviral regimens are urgently needed in regions with high levels of TDR.
- 2 February 2026
- Published by Microbiology Society in Journal of General Virology
- Vol. 107 (2)
Open AccessGeographical and temporal trends of HIV-1 subtypes and drug resistance in China: a nationwide study over two decades (2003–2024)
Objective. This study aims to characterize the 20-year trends in human immunodeficiency virus 1 (HIV-1) subtypes and circulating recombinant forms (CRFs) in China, as well as patterns of transmitted drug resistance (TDR) to antiretroviral therapies commonly used in clinical practice. Methods. We analysed HIV-1 sequences from 81,563 individuals living in China between 2003 and 2024. Subtypes and CRFs were classified using COMET V2.4. Among these, pol gene sequences from 41,486 treatment-naïve individuals were used to assess TDR via the Stanford HIVdb genotypic resistance interpretation program. Results. Over the past two decades, CRF01_AE (43.9%) was the most prevalent HIV-1 strain in China, followed by CRF07_BC (19.0%), subtype B (12.3%), subtype C (8.4%) and CRF08_B (4.9%). However, subtype and CRF distributions varied considerably across provinces. CRF01_AE predominated in provinces such as Liaoning (92.4%), Guangxi (58.7%), Beijing (47.7%) and Hainan (44.8%), while CRF07_BC was dominant in Sichuan (63.6%), Chongqing (53.2%) and Xinjiang (82.7%). TDR analysis revealed elevated resistance to non-nucleoside reverse transcriptase inhibitors in certain provinces, including Yunnan (12.4%), Xinjiang (8.2%), Anhui (7.6%) and Henan (6.7%). In contrast, resistance to nucleoside reverse transcriptase inhibitors and integrase inhibitors remained low (Conclusion. Continued surveillance of HIV-1 genotypes and CRFs is critical, particularly in regions where routine genotypic testing is not implemented. Personalized antiretroviral regimens are urgently needed in regions with high levels of TDR.
- Open Access
Affinity-purified sHBsAg-based virus-like particles as a platform for foreign mRNA binding
- Open Access
- 8 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17859-17873
Anticoronavirus Activity of Uridine Glycoconjugates Containing a 1,2,3-Triazole Moiety
Coronaviruses can spread rapidly to new host species and cause severe respiratory and enteric diseases in vertebrates, including humans. To date, seven coronaviruses have been identified in humans, with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) being the most notorious due to its substantial social and economic impact. Although anti-SARS-CoV-2 vaccines are available, infections remain widespread, highlighting the ongoing need for antiviral treatments. Here, we report the synthesis and evaluation of the activity of uridine glycoconjugates, designed as glycosyltransferase donor-type inhibitors incorporating a 1,2,3-triazole moiety. These compounds were tested against two model coronaviruses: murine hepatitis virus strain A59 (MHV) and human coronavirus strain NL63 (HCoV-NL63). Four of the synthesized compounds demonstrated strong antiviral activity against both viruses, and their efficacy was further confirmed against SARS-CoV-2. Our results suggest that these compounds interfere with the coronavirus infectivity and replication process. Thus, these novel compounds may prove to be effective broad-spectrum antiviral inhibitors.
- 8 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17859-17873
Open AccessAnticoronavirus Activity of Uridine Glycoconjugates Containing a 1,2,3-Triazole Moiety
Coronaviruses can spread rapidly to new host species and cause severe respiratory and enteric diseases in vertebrates, including humans. To date, seven coronaviruses have been identified in humans, with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) being the most notorious due to its substantial social and economic impact. Although anti-SARS-CoV-2 vaccines are available, infections remain widespread, highlighting the ongoing need for antiviral treatments. Here, we report the synthesis and evaluation of the activity of uridine glycoconjugates, designed as glycosyltransferase donor-type inhibitors incorporating a 1,2,3-triazole moiety. These compounds were tested against two model coronaviruses: murine hepatitis virus strain A59 (MHV) and human coronavirus strain NL63 (HCoV-NL63). Four of the synthesized compounds demonstrated strong antiviral activity against both viruses, and their efficacy was further confirmed against SARS-CoV-2. Our results suggest that these compounds interfere with the coronavirus infectivity and replication process. Thus, these novel compounds may prove to be effective broad-spectrum antiviral inhibitors.
- Open Access
- 6 November 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-8
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens
Infectious diseases remain a persistent public health problem and a leading cause of morbidity and mortality in both humans and animals. The most effective method of combating viral infections is the widespread use of prophylactic vaccinations, which are administered to both people at risk of disease and animals that may serve as significant sources of infection. Therefore, it is crucial to develop technologies for the production of vaccines that are highly effective, easy to transport and store, and cost-effective. The protein expression system based on the protozoan Leishmania tarentolae offers several advantages, validated by numerous studies, making it a good platform for producing vaccine antigens. This review provides a comprehensive overview into the potential applications of L. tarentolae for the safe production of effective viral antigens.
- 6 November 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-8
Open AccessLeishmania tarentolae as a platform for the production of vaccines against viral pathogens
Infectious diseases remain a persistent public health problem and a leading cause of morbidity and mortality in both humans and animals. The most effective method of combating viral infections is the widespread use of prophylactic vaccinations, which are administered to both people at risk of disease and animals that may serve as significant sources of infection. Therefore, it is crucial to develop technologies for the production of vaccines that are highly effective, easy to transport and store, and cost-effective. The protein expression system based on the protozoan Leishmania tarentolae offers several advantages, validated by numerous studies, making it a good platform for producing vaccine antigens. This review provides a comprehensive overview into the potential applications of L. tarentolae for the safe production of effective viral antigens.
- Open Access
- 19 June 2024
- Published by Elsevier in Antiviral Research
- Vol. 228, 105941
Influence of adjuvant type and route of administration on the immunogenicity of Leishmania-derived tick-borne encephalitis virus-like particles – A recombinant vaccine candidate
- 19 June 2024
- Published by Elsevier in Antiviral Research
- Vol. 228, 105941
Open AccessInfluence of adjuvant type and route of administration on the immunogenicity of Leishmania-derived tick-borne encephalitis virus-like particles – A recombinant vaccine candidate
- Open Access
- 15 June 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (3) , e0256422
The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
Although several COVID-19 vaccines have been approved worldwide, continuous emergence of new SARS-CoV-2 variants calls for new efficient vaccines against them, providing long-lasting immunity. As the immune response after vaccination is dependent not only on antigen used, but also on other vaccine components, e.g., adjuvants, the purpose of this work was to study the effect of different adjuvants on the immunogenicity of RBD/N SARS-CoV-2 cocktail proteins.
- 15 June 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (3) , e0256422
Open AccessThe Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
Although several COVID-19 vaccines have been approved worldwide, continuous emergence of new SARS-CoV-2 variants calls for new efficient vaccines against them, providing long-lasting immunity. As the immune response after vaccination is dependent not only on antigen used, but also on other vaccine components, e.g., adjuvants, the purpose of this work was to study the effect of different adjuvants on the immunogenicity of RBD/N SARS-CoV-2 cocktail proteins.
- Open Access
- 14 February 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (1) , e0288522
Influence of Dosing Regimen and Adjuvant Type on the Immunogenicity of Novel Recombinant Zika Virus-Like Particles
Considering the transmission of ZIKV and the risk of another epidemic as well as the neurological complications that follow ZIKV infection, the virus remains a serious problem for the human population, especially pregnant women. Therefore, there is a great need to develop new effective vaccine candidates.
- 14 February 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (1) , e0288522
Open AccessInfluence of Dosing Regimen and Adjuvant Type on the Immunogenicity of Novel Recombinant Zika Virus-Like Particles
Considering the transmission of ZIKV and the risk of another epidemic as well as the neurological complications that follow ZIKV infection, the virus remains a serious problem for the human population, especially pregnant women. Therefore, there is a great need to develop new effective vaccine candidates.
- Open Access
- 26 December 2022
- Published by Elsevier in Antiviral Research
- Vol. 209, 105511
Functional characterization and immunogenicity of a novel vaccine candidate against tick-borne encephalitis virus based on Leishmania-derived virus-like particles
- 26 December 2022
- Published by Elsevier in Antiviral Research
- Vol. 209, 105511
Open AccessFunctional characterization and immunogenicity of a novel vaccine candidate against tick-borne encephalitis virus based on Leishmania-derived virus-like particles
- Open Access
- 12 July 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50 (14) , 7991-8007
In vitro reconstitution reveals a key role of human mitochondrial EXOG in RNA primer processing
The removal of RNA primers is essential for mitochondrial DNA (mtDNA) replication. Several nucleases have been implicated in RNA primer removal in human mitochondria, however, no conclusive mechanism has been elucidated. Here, we reconstituted minimal in vitro system capable of processing RNA primers into ligatable DNA ends. We show that human 5′-3′ exonuclease, EXOG, plays a fundamental role in removal of the RNA primer. EXOG cleaves short and long RNA-containing flaps but also in cooperation with RNase H1, processes non-flap RNA-containing intermediates. Our data indicate that the enzymatic activity of both enzymes is necessary to process non-flap RNA-containing intermediates and that regardless of the pathway, EXOG-mediated RNA cleavage is necessary prior to ligation by DNA Ligase III. We also show that upregulation of EXOG levels in mitochondria increases ligation efficiency of RNA-containing substrates and discover physical interactions, both in vitro and in cellulo, between RNase H1 and EXOG, Pol γA, Pol γB and Lig III but not FEN1, which we demonstrate to be absent from mitochondria of human lung epithelial cells. Together, using human mtDNA replication enzymes, we reconstitute for the first time RNA primer removal reaction and propose a novel model for RNA primer processing in human mitochondria.
- 12 July 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50 (14) , 7991-8007
Open AccessIn vitro reconstitution reveals a key role of human mitochondrial EXOG in RNA primer processing
The removal of RNA primers is essential for mitochondrial DNA (mtDNA) replication. Several nucleases have been implicated in RNA primer removal in human mitochondria, however, no conclusive mechanism has been elucidated. Here, we reconstituted minimal in vitro system capable of processing RNA primers into ligatable DNA ends. We show that human 5′-3′ exonuclease, EXOG, plays a fundamental role in removal of the RNA primer. EXOG cleaves short and long RNA-containing flaps but also in cooperation with RNase H1, processes non-flap RNA-containing intermediates. Our data indicate that the enzymatic activity of both enzymes is necessary to process non-flap RNA-containing intermediates and that regardless of the pathway, EXOG-mediated RNA cleavage is necessary prior to ligation by DNA Ligase III. We also show that upregulation of EXOG levels in mitochondria increases ligation efficiency of RNA-containing substrates and discover physical interactions, both in vitro and in cellulo, between RNase H1 and EXOG, Pol γA, Pol γB and Lig III but not FEN1, which we demonstrate to be absent from mitochondria of human lung epithelial cells. Together, using human mtDNA replication enzymes, we reconstitute for the first time RNA primer removal reaction and propose a novel model for RNA primer processing in human mitochondria.